NCT06950814 Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma
| NCT ID | NCT06950814 |
| Status | Recruiting |
| Phase | — |
| Sponsor | West China Hospital |
| Condition | Sarcomatoid Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-04-05 |
| Primary Completion | 2025-05-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2025-04-05 with a primary completion date of 2025-05-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In recent years, researchers have conducted extensive studies on adjuvant therapy following surgical resection of liver cancer, exploring its potential benefits and seeking effective treatment strategies. Given the rarity and high aggressiveness of primary hepatic sarcomatoid carcinoma, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines. Therefore, we conducted a single-center retrospective study to assess the potential benefits of postoperative adjuvant therapy for patients of primary hepatic sarcomatoid carcinoma.
Eligibility Criteria
Inclusion Criteria: 1. patients who underwent liver resection 2. patients' postoperative paraffin pathology and immunohistochemistry results were reviewed to identify those diagnosed with PHSC Exclusion Criteria: 1. patients who received other anti-tumor treatments before surgery, such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), radiation therapy (RT), and systemic therapy; 2. patients diagnosed with other specific types of sarcomas; 3. patients with concurrent other malignancies during the course of PHSC; 4. patients who were lost to follow-up or lacked essential clinical data.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06950814 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sarcomatoid Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06950814 currently recruiting?
Yes, NCT06950814 is actively recruiting participants. Contact the research team at huangjiwei@wchscu.cn for enrollment information.
Where is the NCT06950814 trial being conducted?
This trial is being conducted at Chengdu, China.
Who is sponsoring the NCT06950814 clinical trial?
NCT06950814 is sponsored by West China Hospital. The trial plans to enroll 50 participants.